A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 773-781

  Sorbe, Bengt ^a   Graflund, Marianne ^a   Nygren, Lisa ^a   Horvath, György ^b   Swahn, Marie ^b   Boman, Karin ^c   Bangshöj, René ^d   Lood, Margareta ^d   Malmström, Henric ^e  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carboplatin; Docetaxel; Neurological side effects; Ovarian cancer; Quality of life; Weekly administration

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CONSTIPATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; EDEMA; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; HEARTBURN; HOARSENESS; HUMAN; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; SENSORY NEUROPATHY; SEPTICEMIA; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NERVOUS SYSTEM DISEASES; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS;

EID: 84857165883     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1286     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CaseBase No. 10. International Agency for Research on Cancer, Lyon, 2010.
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996. (Pubitemid 26012496)
3. Copeland LJ, Bookman M and Trimble E; Gynecologic Oncology Group Protocol GOG 182-ICON5: Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5 Gynecol Oncol 90: S1-S7, 2003.
4. Safra T, Menczer J, Bernstein RM, et al: Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol 114: 215-218, 2009.
5. Sehouli J, Stengel D, Mustea A, et al: Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 61: 243-250, 2008. (Pubitemid 350160322)
6. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: 1331-1338, 2009.
7. Kavanagh JJ: Docetaxel in the treatment of ovarian cancer. Oncology 16: 73-81, 2002.
8. Katsumata N: Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89: S9-S15, 2003.
9. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691, 2004. (Pubitemid 39585637)
10. Kushner DM, Connor JP, Sanchez F, et al: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 105: 358-364, 2007. (Pubitemid 46613899)
11. Tinker AV, Gebski V, Fitzharris B, et al: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01. Gynecol Oncol 104: 647-653, 2007. (Pubitemid 46240256)
12. Gupta D, Owers RL, Kim M, et al: A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 113: 327-330, 2009.
13. Safra T, Bernstein Molho R, Menzcher J, et al: A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism. Chemotherapy 55: 298-302, 2009.
14. Terauchi F, Hirano T, Taoka H, et al: Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistent relapsed ovarian cancer: a phase I study. Int J Clin Oncol 8: 348-351, 2003. (Pubitemid 38036089)
15. Berkenblit A, Seiden MV, Matulonis UA, et al: A phase II trial of weekly docetaxel in patients with platinum-resitent epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95: 624-631, 2004. (Pubitemid 39592531)
16. Komiyama S, Tsuji H, Asai S, et al: A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol 6: 299-302, 2005. (Pubitemid 40874044)
17. Calvert AH, Newell DR, Gunbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989. (Pubitemid 19272848)
18. Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
19. Green S and Weiss GR: Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253, 1992. (Pubitemid 23008970)
20. Rustin GJ, Marples M and Nelstrop AE: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10: 3919-3926, 2004. (Pubitemid 38697628)
21. National Institute of Health: Common Terminology Criteria for Adverse Events (Version 3.0). National Institute of Health, Washington, DC, 2003.
22. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual. 3rd edition. EORTC Publications, Brussels, 2001.
23. Micha JP, Goldstein BH, Rettenmaier MA, et al: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17: 771-776, 2007. (Pubitemid 47063333)
24. Penson RT, Dizon DS, Cannistra SA, et al: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28: 154-159, 2010.
25. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 over-expressors and random assignment to trastuzumab or not in HER-2 non-overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642-1649, 2008.
26. Esmaeli B, Hidaji L, Adinin RB, et al: Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98: 504-507, 2003. (Pubitemid 36885989)
27. Oishi T, Kigawa J, Fujiwara K, et al: A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 90: 421-424, 2003. (Pubitemid 36952038)
28. Bezjak A, Tu D, Bacon M, et al: Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in randomized study. J Clin Oncol 22: 4595-4603, 2004. (Pubitemid 41185127)
29. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al: Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24: 579-586, 2006. (Pubitemid 46630419)
30. Schwarz R and Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German popu- lation. Eur J Cancer 37: 1345-1351, 2001. (Pubitemid 32588744)
31. Almadrones L, McGuire DB, Walczak JR, et al: Psychometric evaluation of two scales assessing functional status and peri- pheral neuropathy associated with chemotherapy for ovarian cancer: a Gynecologic Oncology Group study. Oncol Nurs Forum 31: 615-623, 2004.
32. Wenzel L, Huang HQ, Monk BJ, et al: Quality-of-life compa- risons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23: 5605-5612, 2005.
33. Parmar MK, Ledermann JA, Colombo N, Du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in woman with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.